Recombinant Human MMP19 protein(Leu101-Gly256)

• Cat.No.: MMP19-7378H
• Product Overview: Recombinant Human MMP19 (Q99542-1) (Leu101-Gly256) was expressed in E. coli, with a N-terminal Met.

Specification

• Species: Human
• Source: E.coli
• Tag: Non
• Protein Length: 101-256 a.a.
• Form: Lyophilized from sterile 20mM Tris, 100mM NaCl, 0.5M Arg, 5mM CaCl2, 0.03% Brij35, 50uM ZnCl2, 1/0.1mM GSH/GSSG, pH 8.0. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant human MMP19 consists of 157 amino acids and predicts a molecular mass of 17.6 KDa. It migrates as an approximately 18 KDa band in SDS-PAGE under reducing conditions.
• Purity: > 85 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: MMP19 matrix metallopeptidase 19 [ Homo sapiens ]
• Official Symbol: MMP19
• Synonyms: MMP19; matrix metallopeptidase 19; matrix metalloproteinase 19 , MMP18; matrix metalloproteinase-19; RASI 1; MMP-18; MMP-19; matrix metalloproteinase 18; matrix metalloproteinase 19; matrix metalloproteinase-18; matrix metalloproteinase RASI; MMP18; RASI-1
• Gene ID: 4327
• mRNA Refseq: NM_002429
• Protein Refseq: NP_002420
• MIM: 601807
• UniProt ID: Q99542

Citation

Matrix metalloproteinase (MMP)-19-deficient fibroblasts display a profibrotic phenotype

Journal: American Journal of Physiology - Lung Cellular and Molecular Physiology    PubMed ID: 25575513    Data: 2015/3/15

Authors: Paul Jara, Jazmin Calyeca, Annie Pardo

Article Snippet:Cell growth was also analyzed by cell proliferation assay (CyQUANT; Life Technologies, Eugene, OR).Cell growth was also analyzed by cell proliferation assay (CyQUANT; Life Technologies, Eugene, OR).. Mmp19+/+ and Mmp19?/? fibroblasts were incubated in DMEM with 2% FBS alone or in the presence of 100 ng/ml of recombinant human MMP-19 (Creative BioMart, New York, NY).. The fluorescence was determined in a microplate reader with filters set to 480 nm excitation/520 nm emission, and the results are shown as cell proliferation increases relative to basal values ( day 0 ).The fluorescence was determined in a microplate reader with filters set to 480 nm excitation/520 nm emission, and the results are shown as cell proliferation increases relative to basal values ( day 0 ).

Mmp19 gene expression in Mmp19?/? and Mmp19+/+ fibroblasts. The expression of matrix metalloproteinase 19 (MMP-19) was evaluated by quantitative RT-PCR (A) and RT-PCR (B) in 3 different fibroblast cell lines from each genotype. Each cDNA was quantified in triplicate.

Cell migration network deregulated in MMP-19-deficient fibroblasts. The molecular network generated by IPA software shows differentially regulated genes related to p38/MAPK pathway. Red indicates upregulated, green indicates downregulated, white indicates genes that were not in the data set but form part of this network, and gray indicates genes that were added manually. Solid lines indicate direct relationships between molecules, and dashed lines represent indirect interactions. Results represent data obtained from lung fibroblasts derived from 3 mice of each genotype.

Gene expression by Mmp19?/? and Mmp19+/+ fibroblasts. A: expression of α1-collagen XIV, nidogen 2, fibronectin type III domain containing 1, integrin α 11, matrix metalloprotease 14; mRNA was evaluated by quantitative RT-PCR. The expression was normalized to the level of 18S rRNA. B and C: Mmp19+/+ and Mmp19?/? fibroblasts were incubated with or without recombinant MMP-19 (200 ng/ml) for 18 h. Data are expressed as means ± SD from lung fibroblasts derived from 3 Mmp19?/? and 3 Mmp19+/+ mice performed by triplicate; *P < 0.01.

A new generation of topical chronic wound treatments containing specific MMP inhibitors

Journal: Chronic Wound Care Management and Research    Data: 2014/9/1

Authors: Ravi Shrivastava, Claire Janicot, Pedro Neto

Article Snippet:Selection of MMPs involved in eCM destruction Based on literature review, all commercially available purified MMPs were tested.Selection of MMPs involved in eCM destruction Based on literature review, all commercially available purified MMPs were tested.. Purified recombinant human matrix MMP-1 (intestinal collagenase), MMP-2 (gelatinase), MMP-3 (stromelysin 1, progelatinase), MMP-7 (matrilysin, uterine), MMP-8 (neutrophil collagenase), MMP-9 (gelatinase B), MMP-10 (stromelysin-2), MMP-11 (stromelysin-3), MMP12 (macrophage elastase), MMP-13 (collagenase-3), MMP14 (membrane-inserted/MT1-MMP), MMP-15 (MTMMP2/ SMCP-2), MMP-16 (MMP-X2), MMP-17 (MT4-MMP), MMP-19 (MMP-RASI), MMP-20 (enamelysin), MMP-21, MMP-23 (CA-MMP), MMP-24 (MT5-MMP), MMP-26 (endometase/matrilysin), MMP-27 (MMpeptidase 27), and MMP-28 (epilysin) were purchased from Creative-Biomart (Shirley, NY, USA).. All experiments were conducted using a fixed MMP concentration of 10 μg MMP Eq/mL (equivalents of solutes per milliliter), which was selected on the basis of the median MMP concentration in chronic wound fluids.25 MMPs were then associated with each other to identify the group of epithelial or fibroblast cell matrix-destroying MMPs (VB-MMPs).All experiments were conducted using a fixed MMP concentration of 10 μg MMP Eq/mL (equivalents of solutes per milliliter), which was selected on..